Travere Therapeutics' Research & Development rose 0.41% to $51.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $210.2 million, marking a year-over-year decrease of 2.31%. This contributed to the annual value of $217.5 million for FY2024, which is 11.22% down from last year.
Per Travere Therapeutics' latest filing, its Research & Development stood at $51.9 million for Q3 2025, which was up 5.12% from $49.4 million recorded in Q2 2025.
Over the past 5 years, Travere Therapeutics' Research & Development peaked at $66.5 million during Q2 2023, and registered a low of $46.9 million during Q1 2025.
For the 3-year period, Travere Therapeutics' Research & Development averaged around $55.5 million, with its median value being $54.3 million (2024).
Its Research & Development has fluctuated over the past 5 years, first soared by 68.26% in 2021, then declined by 18.29% in 2024.
Quarterly analysis of 5 years shows Travere Therapeutics' Research & Development stood at $53.0 million in 2021, then increased by 9.60% to $58.1 million in 2022, then climbed by 2.86% to $59.7 million in 2023, then climbed by 3.88% to $62.1 million in 2024, then grew by 0.41% to $51.9 million in 2025.
Its last three reported values are $51.9 million in Q3 2025, $49.4 million for Q2 2025, and $46.9 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value